Compare Payoneer Global Inc (PAYO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Sanofi SA — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 39.2× Payoneer Global Inc's market cap, and Sanofi SA pays a 6.01% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Sanofi SA for 94 Days on average.
| PAYO | SNY | |
|---|---|---|
Market Cap | $2.43B | $95.18B |
Volume | 1,342,701 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $7.18 | $52.34 |
52-Week Low | $4.27 | $39.51 |
Typical Hold Time | 61 Days | 94 Days |
Enterprise Value | $2.17B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.15, down slightly by 0.14% with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights Payoneer's renewed partnership with Etsy through 2029 and the company's agreement to be acquired by Nuvei announced in June 2026. Analyst sentiment remains positive with 60% buy ratings despite recent earnings volatility.
The acquisition by Nuvei creates near-term upside potential, but execution risks and margin compression pose challenges. Revenue growth remains solid at 15% volume growth year-over-year, though net income margin has declined from 16.8% in 2024 to 5.8% projected for 2026. The stock's valuation at 51x P/E appears stretched relative to earnings growth, suggesting cautious optimism is warranted.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
